- Datum19.05.2025
- Uhrzeit09:00 - 10:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
Novo Nordisk AS (ADR) Aktie
Verkaufen
Kaufen
Novo Nordisk AS (ADR) Chart
Novo Nordisk AS (ADR) Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (NYSE)
-2,69 %
Intraday
-2,13 %
1 Woche
2,37 %
1 Monat
-25,17 %
Seit Jahresbeginn
-51,62 %
1 Jahr
24,70 %
3 Jahre
101,44 %
5 Jahre
126,85 %
10 Jahre
Passender Service zu Novo Nordisk AS (ADR)
Webinar zu Novo Nordisk AS (ADR)
Kursinformationen (NYSE)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)57,000-148,150
- Jahrestief / Hoch ($)57,000-93,800
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novo Nordisk AS (ADR)
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 31.03.2025 | 2024 | 1,142561 $ | 1,65 % |
| 16.08.2024 | 2024 | 0,5169016 $ | 0,38 % |
| 22.03.2024 | 2023 | 0,9293348 $ | 0,72 % |
| 18.08.2023 | 2022 | 0,43816945 $ | 0,47 % |
| 24.03.2023 | 2022 | 0,5902906 $ | 0,79 % |
| 12.08.2022 | 2022 | 0,2888726 $ | 0,53 % |
| 25.03.2022 | 2021 | 0,5112118 $ | 0,94 % |
| 16.08.2021 | 2021 | 0,27514445 $ | 0,54 % |
| 26.03.2021 | 2020 | 0,461061 $ | 1,37 % |
| 14.08.2020 | 2020 | 0,2588887 $ | 0,77 % |
| 16.08.2019 | 2019 | 0,222621 $ | 0,88 % |
| 27.03.2020 | 2019 | 0,3913024 $ | 1,38 % |
| 17.08.2018 | 2018 | 0,2311635 $ | 0,97 % |
| 22.03.2019 | 2018 | 0,388503 $ | 1,49 % |
| 17.08.2017 | 2017 | 0,2369105 $ | 1,02 % |
| 23.03.2018 | 2017 | 0,402991 $ | 1,64 % |
| 11.08.2016 | 2016 | 0,2267295 $ | 0,96 % |
| 23.03.2017 | 2016 | 0,335184 $ | 1,98 % |
| 18.03.2016 | 2015 | 0,4790705 $ | 1,73 % |
| 19.03.2015 | 2014 | 0,36499 $ | 1,48 % |
| 21.03.2014 | 2013 | 0,415152 $ | 1,84 % |
| 21.03.2013 | 2012 | 0,310179 $ | 1,86 % |
| 22.03.2012 | 2011 | 0,2509455 $ | 1,73 % |
| 25.03.2010 | 2010 | 0,1359188 $ | - |
| 24.03.2011 | 2010 | 0,1885974 $ | - |
| 19.03.2009 | 2008 | 0,1085462 $ | - |
| 13.03.2008 | 2007 | 0,0942309 $ | - |
| 08.03.2007 | 2006 | 0,0619291 $ | - |
| 09.03.2006 | 2005 | 0,0483068 $ | - |
| 10.03.2005 | 2004 | 0,06 kr | - |
| 17.03.2004 | 2003 | 0,055 kr | - |
| 26.03.2003 | 2002 | 0,0261435 $ | - |
| 13.03.2002 | 2001 | 0,041875 kr | - |
| 21.03.2001 | 2000 | 0,1325 kr | - |
| 24.03.2000 | 1999 | 0,0975 kr | - |
| 25.03.1999 | 1998 | 0,0775 kr | - |
| 27.03.1998 | 1997 | 0,0575 kr | - |
| 25.04.1997 | 1996 | 0,0375 kr | - |
| 01.05.1996 | 1995 | 0,025 kr | - |
| 24.04.1995 | 1994 | 0,025 kr | - |
| 26.04.1994 | 1993 | 0,02 kr | - |
| 22.04.1993 | 1992 | 0,06 kr | - |
| 28.04.1992 | 1991 | 0,06 kr | - |
| 19.04.1991 | 1990 | 0,06 kr | - |
| 23.04.1990 | 1989 | 0,06 kr | - |
| 21.04.1989 | 1988 | 0,06 kr | - |
| 21.04.1988 | 1987 | 0,06 kr | - |
| 20.04.1987 | 1986 | 0,06 kr | - |
| 21.04.1986 | 1985 | 0,06 kr | - |
| 13.04.1984 | - | 0,06 kr | - |
| 13.04.1983 | - | 0,051 kr | - |
| 23.04.1982 | - | 0,045 kr | - |
| 19.04.1985 | - | 0,06 kr | - |
Termine von Novo Nordisk AS (ADR)
Keine aktuellen Termine
Beschreibung
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
